<DOC>
	<DOCNO>NCT01175226</DOCNO>
	<brief_summary>This study aim evaluate safety , tolerability effectiveness BTA798 - shorten length reduce symptom human rhinovirus infection ( also know common cold ) , - control asthma symptom , - lower risk asthma symptom worsen subject asthma .</brief_summary>
	<brief_title>A Phase 2 Study BTA798 Asthmatic Adults With Symptomatic Human Rhinovirus Infection</brief_title>
	<detailed_description>Subjects previous diagnosis asthma pre screen within 90 day prior enrolment . If subject develop symptom human rhinovirus ( HRV ) infection visit site assessment . Symptomatic subject meet eligibility criterion invite enroll .</detailed_description>
	<criteria>Male female subject age 1870 year Diagnosis asthma consistent Global Initiative Asthma ( GINA ) step 1 3 Presumptive human rhinovirus infection Current severe asthma exacerbation Severe asthma , GINA step 4 high Uncontrolled clinically significant medical condition , disease event could impact subject safety and/or study evaluation and/or compliance protocol Current smoker , exsmoker &lt; 1 year , history smoking &gt; /=10 pack year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Human rhinovirus</keyword>
	<keyword>Aviragen Therapeutics , Inc .</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>